Pseudosciaena crocea antibacterial protein LcHpAMP212 and application thereof
The large yellow croaker antibacterial protein LcHpAMP212 effectively addresses antibiotic resistance and pollution by targeting bacterial cell membranes and biofilms, offering a sustainable alternative for aquaculture.
Patent Information
- Application Number
- CN202411191219.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-03
AI Technical Summary
The rapid expansion of aquaculture has led to excessive antibiotic use, resulting in drug-resistant strains and environmental pollution, posing a significant threat to human health and food safety, with limited effective alternatives.
Development of a large yellow croaker antibacterial protein LcHpAMP212, characterized by a specific amino acid sequence (SEQ ID NO.1) and nucleotide sequence (SEQ ID NO.2), expressed via a recombinant vector in BL21 (DE3) cells, and purified for use as an antimicrobial agent, disinfectant, feed additive, and preservative.
LcHpAMP212 exhibits strong antimicrobial activity against Gram-positive and Gram-negative bacteria, disrupting cell membranes and inhibiting biofilm formation, maintaining activity across various temperatures and salinities, suitable for aquaculture applications.
Smart Images

Figure CN119060156A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and particularly relates to a large yellow croaker antibacterial protein LcHpAMP212 and an application thereof. Background Art
[0002] Aquaculture is hailed as the fastest-growing food sector globally. However, its rapid expansion has been accompanied by an alarming increase in antibiotic use. Aquaculture producers often use antibiotics even when uncertainty surrounds whether the infection is viral or bacterial, a phenomenon particularly pronounced in low- and middle-income countries in Asia and Africa. Furthermore, compared to developed countries, regulation of antibiotic sales and use in these countries is relatively weak. Although my country has established a strict regulatory system for antibiotic residues in aquatic products, the widespread use of antibiotics in aquaculture remains common. This not only leads to the emergence of drug-resistant strains but also contributes to food safety and water pollution, posing a serious threat to human and public health (Malik H, Singh R, Kaur S, et al. Review of antibiotic use and resistance in foodanimal production in WHO South-East Asia Region. J Infect Public Health. 2023; 16 Suppl 1:172-182.). The World Health Organization's 2022 Global Antimicrobial Resistance and Use Surveillance System report pointed out that in 2019 alone, drug-resistant bacteria caused approximately 1.3 million deaths, and it is estimated that by 2050, this figure will rise to 10 million, far exceeding the number of deaths from cancer, and the direct economic losses caused each year exceed US$2.0 trillion (JuloS, Awosile B. Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries. PLoS One. 2024; 19(2):e0297921.).The World Health Organization has listed antibiotic resistance as one of the top ten public health threats facing humanity and has identified 15 drug-resistant bacteria that pose serious problems (Updated Bacterial Priority Pathogens List (BPPL) 2024, WHObacterial priority pathogenslist, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance). Therefore, limiting the use of antibiotics and seeking green, safe, and effective alternatives has become a top priority.
[0003] To combat infection by diverse pathogens, organisms produce a variety of antimicrobial proteins / peptides. While antimicrobial proteins typically have larger molecular weights than antimicrobial peptides, their mechanisms of action are similar. Antimicrobial proteins / peptides lack specificity and target diverse bacterial species, making it difficult for bacteria to develop resistance to these proteins. One of the key mechanisms by which antimicrobial proteins / peptides kill bacteria is by altering or disrupting the structure and polarity of bacterial cell membranes. The hydrophobic C-termini of many antimicrobial proteins / peptides are first inserted into the hydrophobic region of the cell membrane, thereby causing changes in the membrane conformation; in addition, antimicrobial proteins / peptides can also change the arrangement of membrane lipid molecules and form multiple ion channels on the cell membrane, causing a large amount of cell contents to overflow and cause bacterial death; some antimicrobial proteins / peptides can inhibit the activity of cell wall synthases and destroy the structure and integrity of the cell wall, which is also an important mechanism for causing bacterial death; in addition, some antimicrobial proteins / peptides can also penetrate the cell membrane and reach the inside of the cell, blocking key cell processes, such as interfering with protein / nucleic acid synthesis, protein / enzyme activity, cell division, and normal protein folding, ultimately leading to cell death (Mhlongo JT, Waddad AY, Albericio F, de la Torre BG. Antimicrobial Peptide Synergies for Fighting Infectious Diseases. Adv Sci(Weinh). 2023;10(26):e2300472). Summary of the Invention
[0004] The purpose of the present invention is to provide a large yellow croaker antibacterial protein LcHpAMP212 and application thereof.
[0005] To achieve the above object, the present invention adopts the following technical solutions: A large yellow croaker antimicrobial protein LcHpAMP212, wherein the large yellow croaker antimicrobial protein LcHpAMP212 has an amino acid sequence as shown in SEQ ID NO.1.
[0006] A gene encoding the above-mentioned large yellow croaker antibacterial protein LcHpAMP212, wherein the gene has a nucleotide sequence as shown in SEQ ID NO.2.
[0007] An expression vector comprising the gene encoding the large yellow croaker antibacterial protein LcHpAMP212.
[0008] A host cell comprising the above-mentioned expression vector.
[0009] The above-mentioned method for preparing the large yellow croaker antimicrobial protein LcHpAMP212 comprises the following steps: cloning the gene encoding the large yellow croaker antimicrobial protein LcHpAMP212 into the pET-32a vector through the EcoR Ⅰ / Xho Ⅰ restriction enzyme cutting site to construct a recombinant expression vector pET-32a-LcHpAMP212; transforming the recombinant expression vector pET-32a-LcHpAMP212 into BL21 (DE3) competent cells, inducing expression through IPTG, extracting, and purifying to obtain the large yellow croaker antimicrobial protein LcHpAMP212.
[0010] The applications of the aforementioned large yellow croaker antimicrobial protein LcHpAMP212 include but are not limited to the following: 1) Application in the preparation of antibacterial agents; 2) Application in the preparation of water disinfectants; 3) Application in the preparation of feed additives; 4) Application in the preparation of preservatives.
[0011] Furthermore, the above antibacterial agent is used to fight Vibrio vulnificus, Vibrio alginolyticus, and Staphylococcus aureus.
[0012] The significant advantages of the present invention are: The antimicrobial protein LcHpAMP212 provided by the present invention is a hypothetical protein whose function has not been annotated in the large yellow croaker genome. This invention innovatively identifies its antimicrobial function. The antimicrobial protein LcHpAMP212 exhibits strong antimicrobial activity against both Gram-positive and Gram-negative bacteria, but the antimicrobial mechanisms differ between the two. Scanning electron microscopy results showed that the antimicrobial protein LcHpAMP212 disrupted the cell walls or membranes of three indicator bacteria: Vibrio vulnificus, Vibrio alginolyticus, and Staphylococcus aureus, forming pores. Gel retardation assays showed that the antimicrobial protein LcHpAMP212 bound to the DNA of the Gram-negative bacteria V. vulnificus and V. alginolyticus, but not to the DNA of the Gram-positive bacteria S. aureus. Furthermore, the antimicrobial protein LcHpAMP212 inhibited biofilm formation by these three indicator bacteria. At a temperature of 25-100°C and a salinity of 0-40‰, the antimicrobial protein LcHpAMP212 maintains antimicrobial activity against three indicator bacteria: Vibrio vulnificus, Vibrio alginolyticus, and Staphylococcus aureus, indicating that the antimicrobial protein LcHpAMP212 has the potential to be used as an antimicrobial agent, water disinfectant, feed additive, and preservative, and is suitable for use in seawater environments. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 Figure 3: Expression and purification results of the recombinant LcHpAMP212 protein. M: Protein maker, 1: Empty vector protein expressed without IPTG induction, 2: Empty vector protein expressed with IPTG induction, 3: LcHpAMP212 recombinant protein expressed without IPTG induction, 4: LcHpAMP212 recombinant protein expressed with IPTG induction, 5: Supernatant of LcHpAMP212 expression induced by IPTG, 6: Precipitate of LcHpAMP212 expression induced by IPTG, 7: Purified empty vector protein, 8: Purified LcHpAMP212 recombinant protein.
[0014] Figure 2 : Inhibitory effects of LcHpAMP212 recombinant protein and empty vector protein against Vibrio vulnificus, Vibrio alginolyticus and Staphylococcus aureus.
[0015] Figure 3 : Effects of LcHpAMP212 recombinant protein on the 24h growth curves of Vibrio vulnificus, Vibrio alginolyticus and Staphylococcus aureus.
[0016] Figure 4 : The killing effects of LcHpAMP212 recombinant protein and empty vector protein on Vibrio vulnificus, Vibrio alginolyticus and Staphylococcus aureus were observed under scanning electron microscope.
[0017] Figure 5 Figure 1: Bacterial DNA treated with ultrapure water. Figures 3-7: Bacterial DNA treated with LcHpAMP212 recombinant protein at concentrations of 0.5×MIC, 1.0×MIC, 2.0×MIC, 4.0×MIC, and 8.0×MIC, respectively.
[0018] Figure 6 :Effects of LcHpAMP212 recombinant protein on biofilm formation of Vibrio vulnificus, Vibrio alginolyticus and Staphylococcus aureus.
[0019] Figure 7 : Stability analysis of LcHpAMP212 recombinant protein. DETAILED DESCRIPTION
[0020] In order to make the contents of the present invention easier to understand, the technical solutions of the present invention are further described below in conjunction with specific implementation methods, but the present invention is not limited thereto.
[0021] Unless otherwise specified, the technical solutions described in the present invention are all conventional technologies in the field; the reagents or materials described are all from commercial channels unless otherwise specified.
[0022] Example 1: Recombinant expression and purification of large yellow croaker antimicrobial protein LcHpAMP212 1. The amino acid sequence of the large yellow croaker antimicrobial protein LcHpAMP212 is: MNLWFSHLLVAGLVLTTSALTPEECQPLTKPLSLADSSMLQGRLNFIMGYTDTDAYNAILKSTESYWMKMTPSASDKNELTVHEENKINGSCIGLSFNMTIDGDHVDMSLPNISTVFQVLPGCDGCVVFRANSTASNLSTLFHMMNINIDITDEELTTHAIYLMARETSVKDSDLEQFKQQASCLGFTGEPHFSYDPKNDFCAEGEGSHLSL.
[0023] 2. Gene encoding the antimicrobial protein LcHpAMP212 in large yellow croaker LcHpAMP212 The nucleotide sequence is: .
[0024] 3. Induced expression, extraction and purification of the antimicrobial protein LcHpAMP212 from large yellow croaker: (1) The gene encoding the antimicrobial protein LcHpAMP212 of large yellow croaker was cleaved through the EcoR Ⅰ / Xho Ⅰ restriction enzyme sites. LcHpAMP212 The recombinant expression vector pET-32a-LcHpAMP212 was constructed by cloning into the pET-32a vector.
[0025] (2) The recombinant expression vector pET-32a-LcHpAMP212 was transformed into BL21 (DE3) competent cells and cultured in a shaking incubator at 200 rpm and 37 °C for 5-6 h until the bacterial solution OD 600 When the value reached 0.6, 1.0 mM IPTG was used to induce expression at 200 rpm and 20°C for 16 h to obtain the induced bacterial solution.
[0026] (3) The induced bacterial solution was centrifuged at 7000 × g for 5 min at 4°C. The bacterial pellet was collected, washed three times with 1× PBS buffer (pH 7.4), and then resuspended in 4°C pre-cooled Binding buffer (1 mol / L PBS buffer, 20 mmol / L imidazole; pH 7.4) to obtain a resuspended bacterial solution.
[0027] (4) Place the resuspended bacterial solution on ice and sonicate until the bacterial solution becomes clear and transparent. The sonication conditions are: 35% pulse, 5s on, 5s off.
[0028] (5) The ultrasonically disrupted bacterial suspension was centrifuged at 12,000 × g for 20 min at 4°C to separate the supernatant and precipitate.
[0029] (6) The supernatant was filtered through a 0.45 μm filter membrane and slowly added to a His-tag affinity chromatography column pre-cooled at 4°C. The column was gently shaken on ice for 0.5–1 h to achieve effective binding of the target protein.
[0030] (7) The affinity chromatography column was placed vertically for 5 min, the outflowing liquid was discarded, and the affinity chromatography column was first washed with 4-5 column volumes of washing buffer (1 mol / L PBS buffer, 35 mmol / L imidazole; pH 7.4) to remove non-specifically bound impurities and thus improve the purity of the target protein.
[0031] (8) Add 2-3 mL of elution buffer (1 mol / L PBS buffer, containing 500 mmol / L imidazole, pH 7.4) to the affinity chromatography column to elute the target protein. Repeat the elution 3-4 times and collect the eluate.
[0032] (9) The collected elution liquid was placed in a dialysis bag, dialyzed with 1× PBS buffer (pH 7.4) to remove small molecules such as imidazole, and freeze-dried to obtain LcHpAMP212 recombinant protein dry powder, also known as large yellow croaker antibacterial protein LcHpAMP212 dry powder.
[0033] Figure 1 The expression and purification results of LcHpAMP212 recombinant protein were detected by SDS-PAGE, and finally a soluble purified protein was obtained.
[0034] Example 2: Antibacterial effect of large yellow croaker antimicrobial protein LcHpAMP212 1. Preparation of indicator bacteria: Vibrio vulnificus, Vibrio alginolyticus and Staphylococcus aureus were used as indicator bacteria. The indicator bacteria were inoculated into LB liquid medium at an inoculum volume of 1% (v / v) and cultured at 30°C or 37°C with shaking until the OD 600 =1.0, the oscillation frequency is 200r / min.
[0035] 2. Preparation of double-layer plates: First, pour 10 mL of LB solid medium as the lower plate. Then, take 500 μL of indicator bacteria liquid and mix it with 5 mL of LB liquid medium to form the upper plate. Spread it flat on the solidified lower plate. After air-drying for 5 minutes, use the punching method to divide the culture dish into four equal areas and drill 6 mm holes with a punch.
[0036] 3. Determination of Antibacterial Activity: Adjust the concentration of purified LcHpAMP212 recombinant protein to 500 μg / mL. Add 50 μL to each well and incubate upright at 30°C or 37°C for 12 hours. Observe the antibacterial effect, measure the size of the inhibition zone, and photograph it. Under the same conditions, a group treated with pET-32a empty vector protein served as a negative control.
[0037] Figure 2 The inhibition zone size of LcHpAMP212 recombinant protein against indicator bacteria is shown in Table 1.
[0038] Table 1 Antibacterial activity of LcHpAMP212 recombinant protein Example 3: Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of large yellow croaker antimicrobial protein LcHpAMP212 1. Use 96-well plates to conduct the experiment and adjust the concentration of the cultured indicator bacteria to 1×10 6 CFU / mL for standby use. The final concentrations of the purified LcHpAMP212 recombinant protein were adjusted to 2000 μg / mL, 1000 μg / mL, 500 μg / mL, 250 μg / mL, 125 μg / mL, 62.5 μg / mL, and 31.25 μg / mL by two-fold gradient dilution. 50 μL of the protein to be tested and 50 μL of the indicator bacteria solution were mixed in equal volumes to make the final concentration of the indicator bacteria 5×10 5 CFU / mL. After 24 hours of incubation at 30°C or 37°C, bacterial growth was observed. The concentration of the test protein in the wells without obvious bacterial growth was the MIC value for the test protein against the indicator bacteria. An equal volume of sterile saline was added to the control group. Each experiment was repeated three times.
[0039] 2. Spread all the bacterial solution from the corresponding wells with no obvious bacterial growth onto LB solid medium. Allow to air dry for 5 minutes, then incubate in a 30°C or 37°C incubator for 24 hours and observe bacterial growth. The concentration of the protein to be tested at which no bacterial growth is observed is the MBC of the protein for that indicator bacterium.
[0040] Table 2 shows the MIC and MBC values of the LcHpAMP212 recombinant protein against three indicator bacteria. The MICs of the LcHpAMP212 recombinant protein against Vibrio vulnificus, Vibrio alginolyticus, and Staphylococcus aureus were 250.0 μg / mL, 250.0 μg / mL, and 500.0 μg / mL, respectively. The MBCs of the LcHpAMP212 recombinant protein against Vibrio vulnificus, Vibrio alginolyticus, and Staphylococcus aureus were 500.0 μg / mL, 250.0 μg / mL, and 500.0 μg / mL, respectively.
[0041] Table 2 MIC and MBC of LcHpAMP212 recombinant protein against three indicator bacteria Example 4: Bactericidal kinetics curve of large yellow croaker antimicrobial protein LcHpAMP212 1. Take 50 μL of purified LcHpAMP212 recombinant protein and indicator bacteria solution and mix them in equal volumes to make the final concentration of indicator bacteria OD 600 = 0.1, and the final concentrations of LcHpAMP212 recombinant protein were 0.5×MIC, 1.0×MIC, 2.0×MIC, 4.0×MIC, and 8.0×MIC. Cultures were performed at 30°C or 37°C for 24 h. Changes in indicator bacteria concentration were continuously monitored using a FlexA-200 microplate reader at 1-h intervals. Under the same conditions, the pET-32a empty vector protein-treated group served as the control group.
[0042] Figure 3 The 24-hour growth curves of three indicator bacteria treated with different concentrations of LcHpAMP212 recombinant protein are shown. LcHpAMP212 recombinant protein has a significant inhibitory effect on the growth of the three indicator bacteria, and this is dependent on the protein concentration. At a protein concentration of 1.0×MIC, Vibrio vulnificus and Vibrio alginolyticus entered the bacterial growth plateau after 9 hours, and the bacterial concentration remained at OD 600 ≈0.7; When the protein concentration was 4.0×MIC and 8.0×MIC, the growth of the three bacteria was significantly inhibited, especially Vibrio alginolyticus and Staphylococcus aureus, OD 600 Not exceeding 0.2.
[0043] Example 5: Antibacterial mechanism of large yellow croaker antimicrobial protein LcHpAMP212 - Scanning electron microscopy observation of bacterial cell morphology changes 1. Select Vibrio vulnificus, Vibrio alginolyticus and Staphylococcus aureus as indicator bacteria, collect the shaken cultured bacteria by centrifugation, wash the bacteria three times with PBS buffer (pH 7.0), and finally adjust the bacterial concentration to OD 600= 1.0. Purified LcHpAMP212 recombinant protein was added to the indicator bacterial suspension at a final concentration of 500 µg / mL, and the mixture was incubated at 30°C for 2 hours. The sample was then fixed with 2.5% glutaraldehyde for 3 hours and dehydrated in successive cycles of 50%, 70%, 90%, 95%, and 100% ethanol. Finally, the sample was dried in a 55°C oven overnight, and bacterial changes were observed under a scanning electron microscope. The same procedure was performed, using the empty pET-32a vector protein as a control.
[0044] Figure 4 The effects of LcHpAMP212 recombinant protein and pET-32a empty vector protein on indicator bacteria were observed under scanning electron microscopy. The control group was the pET-32a empty vector protein treatment group. Figure 4 showed that the Vibrio vulnificus control group ( Figure 4 A) The bacteria have obvious morphology, flagella, and are rod-shaped. Figure 4 C) bacteria were rod-shaped and intact with smooth surface. Figure 4 E) is round and spherical, with intact bacterial surface. After LcHpAMP212 recombinant protein treatment, the three indicator bacteria showed different degrees of depression, Vibrio vulnificus ( Figure 4 B) The bacteria are shrunken, the cell membrane is uneven and some flagella have disappeared. Figure 4 D) Bacteria show severe shrinkage and rupture. Staphylococcus aureus ( Figure 4 F) Tiny particles appear on the surface of the bacteria, with obvious depressions.
[0045] Example 6: Antibacterial mechanism of large yellow croaker antimicrobial protein LcHpAMP212 - Gel retardation assay to determine the interaction between protein and bacterial DNA 1. Extract indicator bacterial DNA to a final concentration of 20 ng / µL. Mix 5 µL of each of the purified LcHpAMP212 recombinant protein (final concentrations of 0.5×MIC, 1.0×MIC, 2.0×MIC, 4.0×MIC, and 8.0×MIC) and indicator bacterial DNA in equal volumes. Incubate at 37°C in a water bath for 1 hour, and then analyze the interaction between the LcHpAMP212 recombinant protein and indicator bacterial DNA using 1% agarose gel electrophoresis. Sterile water and pET-32a empty vector protein treatments served as negative controls.
[0046] Figure 5 The results of the gel retardation experiment of bacterial nucleic acid by LcHpAMP212 recombinant protein. When treated with 4.0×MIC and 8.0×MIC protein, the brightness of bacterial nucleic acid decreased, and there was a significant dragging phenomenon, indicating that LcHpAMP212 recombinant protein may form a complex with V. vulnificus DNA, causing gel retardation. At the same time, LcHpAMP212 recombinant protein has the ability to degrade V. vulnificus DNA ( Figure 5 A). When Vibrio alginolyticus was treated with 2.0×MIC, 4.0×MIC, and 8.0×MIC proteins, the brightness of bacterial nucleic acid decreased, but no dragging phenomenon occurred, indicating that the genome of Vibrio alginolyticus was destroyed and degradation occurred ( Figure 5 B). Staphylococcus aureus DNA did not show any changes under the action of different concentrations of LcHpAMP212 recombinant protein, indicating that LcHpAMP212 recombinant protein has no destructive effect on Staphylococcus aureus DNA ( Figure 5 C).
[0047] Example 7: Antibacterial mechanism of large yellow croaker antimicrobial protein LcHpAMP212 - crystal violet method to determine the effect of protein on bacterial biofilm formation 1. Cultivate indicator bacteria to OD 600 =0.6, that is, after the logarithmic growth phase, the bacterial concentration is adjusted to OD 600 = 0.1, 100 μL was added to a 96-well microplate, and an equal volume of purified LcHpAMP212 recombinant protein was added to the bacterial suspension to a final concentration of 0, 1 / 32×MIC, 1 / 16×MIC, 1 / 8×MIC, 1 / 2×MIC, 1×MIC, 2×MIC, 4×MIC, and 8×MIC. Three replicates were set for each group.
[0048] 2. After incubating the 96-well microplate at 30°C or 37°C for 24 hours, discard any unadsorbed bacteria from the wells. Wash the wells three times with PBS buffer to remove floating bacteria. Then, dry the wells in a 55°C oven for 15 minutes to fix the cells. After drying, add 200 μL / well of 1% (w / v) crystal violet stain and stain for 30 minutes.
[0049] 3. Once staining is complete, aspirate the crystal violet solution and rinse three times with PBS buffer until no crystal violet residue remains. Then, oven dry in a 55°C oven for 15 minutes. Once dry, add 200 μL / well of 33% (v / v) glacial acetic acid to fully dissolve the solution.
[0050] 4. Measure OD using a microplate reader 570 The group without LcHpAMP212 recombinant protein was used as the control group. 570 - Treatment Group A 570 ) / control group A 570 ×100% Figure 6The effect of LcHpAMP212 recombinant protein on biofilm formation of three indicator bacteria was analyzed. LcHpAMP212 recombinant protein exhibited significant inhibitory effects on biofilm formation in a concentration-dependent manner. At a concentration of 2.0× the MIC, biofilm formation of Vibrio vulnificus and Vibrio alginolyticus was almost completely inhibited. For Staphylococcus aureus, the degree of inhibition of biofilm formation gradually increased with increasing LcHpAMP212 recombinant protein concentration.
[0051] Example 8: Stability Analysis of Large Yellow Croaker Antimicrobial Protein LcHpAMP212 1. Adjust the concentration of purified LcHpAMP212 recombinant protein and pET-32a empty vector protein to 500 μg / mL and set aside.
[0052] 2. Heat the LcHpAMP212 recombinant protein and the pET-32a empty vector protein in a water bath at 25°C, 50°C, 75°C, and 100°C for 30 min, respectively, and store at room temperature for later use.
[0053] 3. Mix the LcHpAMP212 recombinant protein and the pET-32a empty vector protein with NaCl respectively, so that the final NaCl concentration (salinity) is 0‰, 2.5‰, 5‰, 10‰, 20‰, and 40‰, and store at room temperature until use.
[0054] 4. Antibacterial activity assay: The antibacterial activity was determined using the agarose diffusion method, the same as in Example 2.
[0055] Figure 7 The thermal stability and salt tolerance of the recombinant LcHpAMP212 protein were analyzed. The protein maintained antibacterial activity at temperatures between 25°C and 100°C and salinities between 0‰ and 40‰, indicating that the protein exhibits a certain degree of heat and salt tolerance and is suitable for use in seawater environments.
[0056] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention should fall within the scope of the present invention.
Claims
1. A large yellow croaker antimicrobial protein LcHpAMP212, characterized in that: The large yellow croaker antibacterial protein LcHpAMP212 has an amino acid sequence as shown in SEQ ID NO.
1.
2. A gene encoding the antimicrobial protein LcHpAMP212 of large yellow croaker according to claim 1, characterized in that: The gene has a nucleotide sequence as shown in SEQ ID NO.
2.
3. An expression vector, characterized in that: The expression vector comprises the gene according to claim 2.
4. A host cell, characterized in that: The host cell comprises the expression vector according to claim 3.
5. A method for preparing the large yellow croaker antimicrobial protein LcHpAMP212 according to claim 1, characterized in that: The gene described in claim 2 is cloned into the pET-32a vector through the EcoRⅠ / Xho Ⅰ restriction enzyme cutting site to construct a recombinant expression vector pET-32a-LcHpAMP212; the recombinant expression vector pET-32a-LcHpAMP212 is transformed into BL21 (DE3) competent cells, and the large yellow croaker antibacterial protein LcHpAMP212 is obtained by inducing expression, extraction and purification through IPTG.
6. The use of the large yellow croaker antimicrobial protein LcHpAMP212 as claimed in claim 1, characterized in that: Including but not limited to the following: 1) Application in the preparation of antibacterial agents; 2) Application in the preparation of water disinfectants; 3) Application in the preparation of feed additives; 4) Application in the preparation of preservatives.
7. The use according to claim 6, characterized in that: The antibacterial agent is used for resisting Vibrio vulnificus, Vibrio alginolyticus and Staphylococcus aureus.
